Merging Science and Tech

The landscape of drug discovery is evolving as scientists increasingly collaborate with software engineers to manage the overwhelming data generated by modern experiments. With advancements in molecular tools, labs are now producing data streams that rival those of major tech companies. This shift necessitates a new breed of investment firms that understand both the scientific and technological aspects of biotech, enabling them to support innovative solutions for contemporary challenges in drug development.